BAJAJ BROKING
Alembic Pharma's API-III facility in Karakhadi, Gujarat, successfully cleared the USFDA inspection with zero observations. This positive outcome strengthens the company's compliance record, positively influencing Alembic Pharma share price and market sentiment.
Alembic Pharmaceuticals announced that its API-III facility at Karakhadi, Gujarat, has successfully passed the US Food and Drug Administration (USFDA) inspection without receiving any Form 483 observations. The inspection, which was conducted from 17th March to 21st March 2025, was a scheduled Good Manufacturing Practices (GMP) inspection aimed at evaluating the facility’s compliance with USFDA regulations. The successful inspection without any observations highlights Alembic Pharma's commitment to maintaining high standards of quality and safety in its pharmaceutical manufacturing processes.
Also read: Ola Electric Begins S1 Gen 3 Scooter Deliveries Across India
Alembic Pharma’s API-III facility at Karakhadi cleared USFDA inspection without any Form 483 observations.
Inspection was conducted from 17th March to 21st March 2025.
This was a scheduled GMP inspection, confirming compliance with USFDA standards.
Positive inspection outcome may influence Alembic Pharma share price.
Alembic Pharma continues to maintain high standards in quality and manufacturing practices.
Also read: NCC Wins Rs 1,480.34 Crore Medical Redevelopment Project in Bihar
Alembic Pharmaceuticals is a prominent player in the pharmaceutical industry, known for its vertically integrated research and development capabilities. Despite the positive inspection result, the company reported a decline in net profit for Q3 FY25. The consolidated net profit fell by 23.29% to Rs 138.42 crore, compared to Rs 180.45 crore in Q3 FY24. However, the revenue from operations increased by 3.81% year on year (YoY), amounting to Rs 1,692.74 crore in Q3 FY25.
Financial Metrics | Q3 FY25 | Q3 FY24 | Change (%) |
Net Profit | Rs 138.42 crore | Rs 180.45 crore | -23.29 |
Revenue from Operations | Rs 1,692.74 crore | Rs 1,630.14 crore | +3.81 |
The Alembic Pharma share price is expected to remain in focus following the successful USFDA inspection at the API-III facility. The positive development comes amid a challenging financial period marked by a decline in net profit. Despite this, the company’s revenue growth signals stability in operations. Market sentiment may react positively to the successful inspection, which reinforces the company's commitment to compliance and quality standards.
Period | Change (%) |
Year-to-Date | -10.25 |
Six Months | -5.34 |
One Month | +3.12 |
Closing Price | Rs 600 |
Market Cap | Rs 12,000 crore |
Alembic Pharma’s successful clearance of the USFDA inspection at its API-III facility is a significant milestone, reflecting the company’s adherence to stringent regulatory standards. While the financial performance shows a decline in net profit, the positive inspection outcome may boost investor confidence, potentially impacting the Alembic Pharma share price favourably. The company’s continued focus on quality and compliance ensures sustained growth and stability in the long term.
Also read: Air India Resumes London Heathrow Services After Power Outage
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer
Share this article:
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading